论文部分内容阅读
目的探索丙型肝炎病毒（ＨＣＶ）Ｃ３３抗原在正常人群及各类临床病人血清及肝组织中分布状况。方法用人工合成的ＨＣＶ核心抗原Ｃ３３肽（含３３个氨基酸）与小鼠血清白蛋白，经异型双功能交联剂ＳＰＤＰ连接后免疫Ｂａｌｂ／Ｃ小鼠，制成２株Ｃ３３肽单克隆抗体（ＭｃＡｂ），分别用作包被抗体和酶标抗体，建立检测血清中Ｃ３３肽抗原的酶联免疫吸附试验（ＥＬＩＳＡ），共检测了１２３６例各类病人。并用免疫荧光及固相免疫酶法检测肝活检组织中的ＨＣＶＣ３３肽抗原。结果急性丙型肝炎（ＨＣ）患者，Ｃ３３肽的阳性检出率为１４．０％（６／４３）；仅抗－ＨＣＶＩｇＧ阳性患者Ｃ３３肽的阳性检出率为８．８％（３５／３９６）；慢性丙型肝炎患者为６．５％（４／６２）；白血病患者为４．３％（１／２３）；血透病人为３．３％（１９／５７６）；普通住院病人为１．５％（２／１３６）；正常供血员为１．４％（６／４３８）。肝活检免疫荧光、固相免疫酶检测显示ＨＣＶＣ３３肽在细胞核、细胞质、细胞膜上均有表达，在胞质中或集中于全胞质一侧或弥散分布于胞质中。结论ＨＣＶＣ３３抗原测定，可以作为ＨＣＶ感染的标志物之一。
Objective To explore the distribution of hepatitis C virus (HCV) C33 antigen in serum and liver of normal people and various clinical patients. Methods Balb / C mice were immunized with the synthetic C core peptide of C33 (containing 33 amino acids) and mouse serum albumin (BSDP) through the heterodifunctional bifunctional crosslinker SPDP. Two C33 peptide monoclonal antibodies McAb) were used as the coating antibody and enzyme-labeled antibody, respectively, to establish ELISA for the detection of C33 peptide antigen in serum. A total of 1236 cases of various types of patients were detected. The HCVC33 peptide antigen in liver biopsy was detected by immunofluorescence and solid phase immunoenzymatic assay. Results The positive detection rate of C33 peptide in patients with acute hepatitis C (HC) was 14.0% (6/43). The positive detection rate of C33 peptide in anti-HCV-IgG positive patients was 8.8% (35/396 ); 6.5% (4/62) of patients with chronic hepatitis C; 4.3% (1/23) of patients with leukemia; 3.3% (19/576) of hemodialysis patients; 1 .5% (2/136); normal blood donors was 1.4% (6/438). Liver biopsy immunofluorescence, solid phase immunoenzyme assay showed HCVC33 peptide in the nucleus, cytoplasm, cell membrane are expressed in the cytoplasm or concentrated on the side of the whole cytoplasm or dispersed in the cytoplasm. Conclusion HCVC33 antigen can be used as one of the markers of HCV infection.